Japan's drug pricing policy and U.S. postponement of new drug sales

Asahi Shimbun reported on recent developments in drug pricing and market access. In Japan, authorities are revising the drug pricing policy that determines reimbursement levels. The policy changes aim to balance affordability with pharmaceutical innovation. Meanwhile, the United States is experiencing delays in the launch of new medicines. The U.S. postponements stem from regulatory and pricing negotiations. Both regions face pressure to manage healthcare costs while ensuring patient access. Industry stakeholders are watching the policy shifts for potential impacts on revenue. The report suggests that ongoing discussions could shape future drug availability worldwide.